[go: up one dir, main page]

AR096875A1 - Composiciones de hialuronano de gran elasticidad y sus usos - Google Patents

Composiciones de hialuronano de gran elasticidad y sus usos

Info

Publication number
AR096875A1
AR096875A1 ARP140102559A ARP140102559A AR096875A1 AR 096875 A1 AR096875 A1 AR 096875A1 AR P140102559 A ARP140102559 A AR P140102559A AR P140102559 A ARP140102559 A AR P140102559A AR 096875 A1 AR096875 A1 AR 096875A1
Authority
AR
Argentina
Prior art keywords
composition
hyaluronan
pharmaceutically active
joint
post
Prior art date
Application number
ARP140102559A
Other languages
English (en)
Inventor
A Balazs Endre
Belmonte Carlos
Original Assignee
Matrix Biology Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Biology Inst filed Critical Matrix Biology Inst
Publication of AR096875A1 publication Critical patent/AR096875A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende hialuronano, en donde: el hialuronano está presente en dicha composición en una concentración mayor de aproximadamente 30 mg/ml; el hialuronano tiene un peso molecular promedio de entre aproximadamente 1 y aproximadamente 2 millones; el hialuronano no está entrecruzado y/o está sustancialmente libre de modificaciones químicas; y en donde la composición está sustancialmente libre de otras sustancias farmacéuticamente activas. Reivindicación 2: La composición de la reivindicación 1, en donde la otra sustancia farmacéuticamente activa es una proteína. Reivindicación 3: La composición de la reivindicación 1, en donde la otra sustancia farmacéuticamente activa es un glicosaminoglicano que es diferente del hialuronano. Reivindicación 4: La composición de la reivindicación 1, en donde la otra sustancia farmacéuticamente activa es hidroxipropilmetilcelulosa. Reivindicación 6: La composición de la reivindicación 5, en donde el anestésico tópico es lidocaína o bupivacaína. Reivindicación 9: La composición de la reivindicación 8, en donde la solución amortiguadora es solución salina amortiguada con fosfato (PBS). Reivindicación 10: La composición de la reivindicación 1, en donde la composición tiene una elasticidad de al menos aproximadamente 200 Pascales cuando se mide a una frecuencia de 0,5 Hz. Reivindicación 28: Un método para reducir al menos un síntoma asociado con disfunción de la articulación, el método comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente eficaz de la composición de la reivindicación 1, reduciendo de este modo al menos un síntoma asociado con disfunción de la articulación. Reivindicación 29: El método de la reivindicación 28, en donde la disfunción de la articulación es dolor de articulación o disfunción de la articulación asociada con osteoartritis, post-artroscopia, post-ortoplastia, post-lesión o inmovilización prolongada. Reivindicación 39: Un dispositivo que comprende la composición de la reivindicación 1 ó 14. Reivindicación 40: El dispositivo de la reivindicación 39, en donde el dispositivo es una jeringa precargada.
ARP140102559A 2013-07-10 2014-07-10 Composiciones de hialuronano de gran elasticidad y sus usos AR096875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361844645P 2013-07-10 2013-07-10

Publications (1)

Publication Number Publication Date
AR096875A1 true AR096875A1 (es) 2016-02-03

Family

ID=51261252

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140102559A AR096875A1 (es) 2013-07-10 2014-07-10 Composiciones de hialuronano de gran elasticidad y sus usos
ARP230102360A AR130403A2 (es) 2013-07-10 2023-09-06 Composiciones de hialuronano con elasticidad alta y sus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP230102360A AR130403A2 (es) 2013-07-10 2023-09-06 Composiciones de hialuronano con elasticidad alta y sus usos

Country Status (8)

Country Link
US (5) US9492474B2 (es)
EP (3) EP3019177B1 (es)
JP (5) JP6357228B2 (es)
AR (2) AR096875A1 (es)
ES (2) ES2837626T3 (es)
PL (2) PL3019177T3 (es)
PT (2) PT3019177T (es)
WO (1) WO2015006460A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3019177T (pt) 2013-07-10 2020-12-30 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
HUE054874T2 (hu) * 2015-09-24 2021-10-28 Matrix Biology Inst Magas elaszticitású hialuronán készítmények és alkalmazási eljárások
WO2019138019A2 (en) 2018-01-10 2019-07-18 The Provost, Fellows, Scholars And Other Members Of Board Of Trinity College Dublin System and methods for sealing a channel in tissue
WO2020144372A1 (en) 2019-01-10 2020-07-16 The Provost, Fellows, Scholars And Other Members Of Board Of Trinity College Dublin Composite viscoelastic hydrogel, and uses thereof for sealing a channel in tissue
EA202092472A1 (ru) 2018-04-18 2021-03-25 Ай.КОМ МЕДИКАЛ ГМБХ Высокомолекулярная гиалуроновая кислота для лечения и предупреждения тяжелого заболевания глазной поверхности
WO2020157570A1 (en) 2019-01-31 2020-08-06 i.com medical GmbH Hyaluronic acid for relief of idiopathic ocular pain
EP3969057B1 (en) * 2019-05-17 2025-12-17 The Governing Council of the University of Toronto Sustained release local anesthetic hydrogel composition

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4517295A (en) 1983-02-18 1985-05-14 Diagnostic, Inc. Hyaluronic acid from bacterial culture
LU85582A1 (fr) 1983-10-11 1985-06-04 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique,procedes pour leur preparation et compositions pharmaceutiques les contenant
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5403592A (en) 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
AU620821B2 (en) 1987-08-25 1992-02-27 Macnaught Pty Limited Hyaluronic acid lubricating compounds
EP0414373B2 (en) * 1989-07-24 2001-04-25 Allergan Pharmaceuticals (Ireland) Limited Stable solution of hyaluronate in a balanced salt medium
CA2060223C (en) 1991-02-12 1999-07-20 Clarence C. Lee Injectable medical lubricating fluid composition and method of use
US5234914A (en) 1991-06-11 1993-08-10 Patent Biopharmaceutics, Inc. Methods of treating hemorrhoids and anorecial disease
AU682670B2 (en) 1993-02-05 1997-10-16 Becton Dickinson & Company Syringe needle isolation device
US5583120A (en) 1993-08-04 1996-12-10 Patent Biopharmaceutics, Inc. Hyaluronic acid-urea pharmaceutical compositions and uses
US5607400A (en) 1995-05-19 1997-03-04 Becton, Dickinson And Company Pre-fillable syringe and stopper assembly therefor
IT1277707B1 (it) 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JPH09173450A (ja) 1995-12-26 1997-07-08 Nissho Corp プレフィルドシリンジ
JP3293122B2 (ja) 1996-12-13 2002-06-17 ニプロ株式会社 プレフィルドシリンジ
SE9700827D0 (sv) * 1997-03-07 1997-03-07 Pharmacia & Upjohn Ab Ophthalmic composition
RU2126669C1 (ru) 1997-04-25 1999-02-27 Новокузнецкий государственный институт усовершенствования врачей Способ лечения синдрома сухого глаза
SE9703425D0 (sv) 1997-09-23 1997-09-23 Pharmacia & Upjohn Ab Prefilled ampooules and manufacture thereof
DE19751219A1 (de) 1997-11-19 1999-05-27 Vetter & Co Apotheker Spritze, insbesondere vorgefüllte Spritze, oder Karpule
US6189292B1 (en) 1998-03-13 2001-02-20 Becton Dickinson And Company Method and apparatus for manufacturing, filling and packaging medical devices and medical containers
ITPD980169A1 (it) 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
JP3591636B2 (ja) 2000-04-03 2004-11-24 ニプロ株式会社 プレフィルドシリンジ
ATE250924T1 (de) 2000-04-07 2003-10-15 Medidom Lab Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel
US7635489B2 (en) 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
JP2003119147A (ja) * 2001-10-10 2003-04-23 Raku:Kk ヒアルロン酸化合物の水溶液組成物
JP4436131B2 (ja) 2001-11-21 2010-03-24 イオルテク ヒアルロン酸を安定化させる組成物
US7820194B2 (en) 2001-12-21 2010-10-26 Alcon, Inc. Combinations of viscoelastics for use during surgery
JP4141156B2 (ja) 2002-03-15 2008-08-27 日本ベクトン・ディッキンソン株式会社 プランジャ後退制限機構付きプレフィルドシリンジ
AU2003281199A1 (en) 2002-07-02 2004-01-23 Terumo Kabushiki Kaisha Syringe and prefilled syringe
BRPI0312331A2 (pt) 2002-07-03 2016-06-28 Pericor Science Inc composições de ácido hialurônico e métodos de emprego.
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
DE10254321A1 (de) 2002-11-21 2004-06-17 Arzneimittel Gmbh Apotheker Vetter & Co. Ravensburg Vorgefüllte Spritze
JP2004229750A (ja) 2003-01-28 2004-08-19 Nipro Corp プレフィルドシリンジ及びそのバレルの製造方法
US20040167480A1 (en) 2003-02-21 2004-08-26 Advanced Medical Optics, Inc. Administration of multiple viscoelastic solutions with a multi-compartment syringe
JP2004262777A (ja) 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
US20050059639A1 (en) 2003-09-11 2005-03-17 Wei Edward T. Ophthalmic compositions and method for treating eye discomfort and pain
US20050075611A1 (en) 2003-10-01 2005-04-07 Hetzler Kevin G. Low extractable, thermoplastic syringe and tip cap
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7544671B2 (en) 2004-05-07 2009-06-09 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
US8372814B2 (en) 2004-06-07 2013-02-12 Ista Pharmaceuticals, Inc. Ophthalmic formulations and uses thereof
WO2006067608A1 (en) 2004-12-22 2006-06-29 Laboratoire Medidom S.A. Aqueous formulations based on sodium hyaluronate for parenteral use
CN104689460B (zh) * 2004-12-30 2018-03-13 建新公司 用于关节内粘弹性补充的方案
US8388995B1 (en) 2006-02-03 2013-03-05 Auburn University Controlled and extended delivery of hyaluronic acid and comfort molecules via a contact lens platform
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
ITPD20050056A1 (it) 2005-03-02 2006-09-03 Fidia Farmaceutici Derivati ammidici del'acido ialuronico in osteoartrosi
US7767710B2 (en) 2005-05-25 2010-08-03 Calosyn Pharma, Inc. Method for treating osteoarthritis
DE102005055275A1 (de) 2005-11-17 2007-05-24 Ursapharm Arzneimittel Gmbh & Co. Kg Phosphatfreie pharmazeutische Zusammensetzung sowie deren Verwendung
EP1951761B1 (en) * 2005-11-22 2011-01-05 Centre National De La Recherche Scientifique (Cnrs) New derivatives of hyaluronic acid, their preparation process and their uses
US7988675B2 (en) 2005-12-08 2011-08-02 West Pharmaceutical Services Of Delaware, Inc. Automatic injection and retraction devices for use with pre-filled syringe cartridges
WO2007070547A2 (en) 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
JP4682850B2 (ja) 2006-01-12 2011-05-11 ニプロ株式会社 プレフィルドシリンジ
EP1981491A4 (en) 2006-01-25 2009-09-23 Aciex Inc COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DROUGHT
US7674781B2 (en) 2006-04-28 2010-03-09 Heather Sheardown Hyaluronic acid-retaining polymers
US20080050335A1 (en) 2006-07-25 2008-02-28 Osmotica Corp. Ophthalmic Solutions
EP2489338B1 (en) 2006-08-28 2014-05-14 Rexaderm, INC. Dry wound dressing and drug delivery system
ITMI20061668A1 (it) 2006-09-01 2008-03-02 Schiena Michele Giuseppe Di Composizione a base di acido ialuronico e suoi sali per il trattamento di lesioni epiteliali
AU2007320123A1 (en) 2006-11-17 2008-05-22 Agency For Science, Technology And Research Porous polymeric material with cross-linkable wetting agent
EP1994934A4 (en) 2006-12-05 2010-03-10 Glycoscience Lab Inc THERAPEUTIC AGENT AGAINST DEGENERATIVE ARTHRITIS
FR2918276B1 (fr) * 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
WO2009111159A2 (en) 2008-03-03 2009-09-11 New York University Biocompatible materials containing stable complexes of tsg-6 and hyaluronan and method of using same
WO2009122541A1 (ja) * 2008-03-31 2009-10-08 Inui Hiroaki ヒト胚の体外受精及び培養用培養液及びヒト胚の体外受精及び培養方法
CN102177180A (zh) 2008-04-04 2011-09-07 犹他州大学研究基金会 烷基化半合成的糖胺聚糖醚及其制备和使用方法
FR2938187B1 (fr) 2008-11-07 2012-08-17 Anteis Sa Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur
CA2749034C (en) * 2009-01-07 2019-01-15 Robert John Petrella Treatment of soft tissue injury using hyaluronic acid and botulinum toxin
US20100178317A1 (en) 2009-01-09 2010-07-15 Burke Susan E Lens Care Solutions with Hyaluronic Acid
US8979821B2 (en) 2009-04-14 2015-03-17 Fezza Family Properties, Llc Lacrimal filler
US20100303915A1 (en) 2009-06-02 2010-12-02 Abbott Medical Optics Inc. Therapeutic opthalmic emulsions
AU2010255540A1 (en) 2009-06-05 2012-01-19 Edward Tak Wei Treatment of eye discomfort by topical administration of a cooling agent to the external surface of the eyelid
WO2011031852A1 (en) 2009-09-10 2011-03-17 Boston Foundation For Sight Sodium channel blocker delivery system with scleral lens
CN102781463A (zh) 2009-10-07 2012-11-14 戈诺珍公司 用于皮肤再生的方法和组合物
US20110171310A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
ES2585388T5 (es) 2010-03-22 2019-08-08 Allergan Inc Hidrogeles reticulados de polisacárido y proteína-polisacárido para aumento de tejido blando
US20130209531A1 (en) 2010-06-08 2013-08-15 University Of Utah Research Foundation Applications of partially and fully sulfated hyaluronan
US20130303695A1 (en) 2010-09-02 2013-11-14 Heather Sheardown Hyaluronic acid-containing biopolymers
EP2614838B1 (en) 2010-09-10 2016-04-20 Santen Pharmaceutical Co., Ltd. Diquafosol and hyaluronic acid or salts thereof for the treatment of dry eye
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
WO2012143876A1 (en) * 2011-04-19 2012-10-26 Anteis S.A. A sterile and injectable aqueous formulation for administration in the intra-articular space of an intra-articular joint
GB201118586D0 (en) 2011-10-27 2011-12-07 Turzi Antoine New A-PRP medical device, manufacturing machine and process
DK2596796T3 (da) 2011-11-24 2014-01-27 Quimera Ingenieria Biomedica S L Kompleks opnået af hyaluronsyre eller et salt deraf samt chondroitinsulfatblandinger
EP2817031A4 (en) 2012-02-22 2015-08-05 Tufts College COMPOSITIONS AND METHOD FOR THE ORGANIC ADMINISTRATION OF A THERAPEUTIC ACTIVE SUBSTANCE
EP2818172A4 (en) 2012-02-22 2016-02-17 Hyaluronan Res Inst Inc TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
UA113434C2 (uk) 2012-05-04 2017-01-25 Алкон Рісерч, Лтд. Офтальмологічна композиція з поліпшеним захистом від зневоднювання й утриманням
FR2991876B1 (fr) 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
FR2994846B1 (fr) 2012-08-29 2014-12-26 Vivacy Lab Composition, sterilisee, comprenant au moins un acide hyaluronique et de l'ascorbyl phosphate de magnesium
LT2950783T (lt) 2013-02-01 2019-10-25 Allergan Inc Dirbtinės ašaros, kurių sudėtyje yra natrio hialuronato ir karboksimetilceliuliozės
US9226938B2 (en) 2013-03-14 2016-01-05 RMG Rehabilitation Management Group, LP Combinatorial therapy for treatment of osteoarthritis of the knee
SG11201507724UA (en) 2013-03-25 2015-10-29 Univ Tokyo Nat Univ Corp Plant cultivation method
ITMI20130883A1 (it) 2013-05-30 2014-12-01 Eurores S R L Composizioni farmaceutiche comprendenti collagene e sodio ialuronato
PT3019177T (pt) 2013-07-10 2020-12-30 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e suas utilizações
CA2931039C (en) 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
AU2014352672B2 (en) 2013-11-25 2018-11-29 Deuteria Biomaterials, Llc Deuterium-enriched hyaluronan
FR3015290B1 (fr) 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
HUE054874T2 (hu) 2015-09-24 2021-10-28 Matrix Biology Inst Magas elaszticitású hialuronán készítmények és alkalmazási eljárások

Also Published As

Publication number Publication date
AR130403A2 (es) 2024-12-04
JP6598929B2 (ja) 2019-10-30
JP6357228B2 (ja) 2018-07-11
US20250352572A1 (en) 2025-11-20
JP2019214632A (ja) 2019-12-19
WO2015006460A1 (en) 2015-01-15
US10383890B2 (en) 2019-08-20
EP3019177B1 (en) 2020-11-04
EP4137139A1 (en) 2023-02-22
EP3613423B1 (en) 2022-10-26
JP7025039B2 (ja) 2022-02-24
JP2016526573A (ja) 2016-09-05
US11524027B2 (en) 2022-12-13
US20150018303A1 (en) 2015-01-15
EP3019177A1 (en) 2016-05-18
US20200030363A1 (en) 2020-01-30
US20210161947A1 (en) 2021-06-03
US10933085B2 (en) 2021-03-02
PT3613423T (pt) 2022-12-07
JP2022058871A (ja) 2022-04-12
US20170071974A1 (en) 2017-03-16
ES2837626T3 (es) 2021-07-01
PL3613423T3 (pl) 2023-02-13
US9492474B2 (en) 2016-11-15
PT3019177T (pt) 2020-12-30
EP3613423A1 (en) 2020-02-26
JP2024028669A (ja) 2024-03-04
PL3019177T3 (pl) 2021-04-19
ES2933549T3 (es) 2023-02-10
JP2018138622A (ja) 2018-09-06

Similar Documents

Publication Publication Date Title
AR130403A2 (es) Composiciones de hialuronano con elasticidad alta y sus usos
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
BR112022013150A2 (pt) Derivado da insulina
Pires et al. Hyper‐inflammation and complement in COVID‐19
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
EP4353818A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
MX2009000812A (es) Soluciones de metotrexato concentradas.
BR112015027555A2 (pt) dispositivos médicos que incluem adaptador de frasco com módulo de fármaco seco em linha
MX389346B (es) Formulaciones de anticuerpos monoclonales de alta concentración.
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2014530873A5 (es)
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
EP4606430A3 (en) Use of il-22 dimer in manufacture of a medicament for intravenous administration
EA201201617A1 (ru) Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы
AR112482A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry
CY1113683T1 (el) Συστημα συσκευασιας για φαρμακευτικες συνθεσεις και kit για ενδοφλεβια χορηγηση
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
UA114088C2 (xx) Лікарська композиція з пролонгованим вивільненням для ін'єкцій
Kelly et al. Osteoarthritis and beyond: a consensus on the past, present, and future of hyaluronans in orthopedics
JP2014504613A5 (es)
MX373378B (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
RU2012100621A (ru) Композиция для инъекций, содержащая гидроксихлорохин, для местного применения при лечении геморроя
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas
UY32670A (es) Utilizacion de alfa -1-antitripisina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica

Legal Events

Date Code Title Description
FC Refusal